Literature DB >> 11756981

Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.

Tetsuya Kimura1, Kazuhisa Yoshimura, Kumiko Nishihara, Yosuke Maeda, Shintaro Matsumi, Atsushi Koito, Shuzo Matsushita.   

Abstract

Longitudinal changes in neutralizing antibody responses against autologous human immunodeficiency virus (HIV) type 1 were investigated in 19 chronically infected patients who were undergoing highly active antiretroviral therapy (HAART). Reconstitution of or increase in neutralization activity was observed in 4 of 19 patients during HAART, but neutralization activity was more or less unchanged in most patients. Three of 4 patients with increased neutralization activity had low-level viral rebound ("blips") during HAART. No correlation was found between neutralization activity and HIV-specific CD4+ T cell frequencies. There was a correlation between neutralization activity and CD4+ T cell counts. The reconstituted antibody represented limited cross-reactivity, compared with that of preexisting antibody. Binding activity to monomeric gp120, V2, and V3 peptides was reduced. Both prolonged virus suppression, for CD4+ T cell recovery, and blips, for stimulation of the immune system in vivo, may be required for development of neutralizing antibody in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756981     DOI: 10.1086/338099

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.

Authors:  Natascha Ching; Karin A Nielsen-Saines; Jaime G Deville; Lian S Wei; Eileen Garratty; Yvonne J Bryson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

2.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

5.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation.

Authors:  Sheila M Keating; Debra Hanson; Mila Lebedeva; Oliver Laeyendecker; N'ko L Ali-Napo; S Michele Owen; Susan L Stramer; Richard D Moore; Philip J Norris; Michael P Busch
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

7.  Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Authors:  Erin E Verity; Dimitra Zotos; Kim Wilson; Catherine Chatfield; Victoria A Lawson; Dominic E Dwyer; Anthony Cunningham; Jennifer Learmont; Wayne Dyer; John Sullivan; Melissa Churchill; Steven L Wesselingh; Dana Gabuzda; Paul R Gorry; Dale A McPhee
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

Review 8.  Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.

Authors:  Martyn A French; M Christian Tjiam; Laila N Abudulai; Sonia Fernandez
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.